JP2014510774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510774A5 JP2014510774A5 JP2014504312A JP2014504312A JP2014510774A5 JP 2014510774 A5 JP2014510774 A5 JP 2014510774A5 JP 2014504312 A JP2014504312 A JP 2014504312A JP 2014504312 A JP2014504312 A JP 2014504312A JP 2014510774 A5 JP2014510774 A5 JP 2014510774A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- aryl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 44
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 125000003118 aryl group Chemical group 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000002837 carbocyclic group Chemical group 0.000 claims 12
- PCPQWYHRMVULIX-UHFFFAOYSA-P [1-[2,3-dihydroxy-4-[4-(oxoazaniumylmethylidene)pyridin-1-yl]butyl]pyridin-4-ylidene]methyl-oxoazanium;dinitrate Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C1=CC(=C[NH+]=O)C=CN1CC(O)C(O)CN1C=CC(=C[NH+]=O)C=C1 PCPQWYHRMVULIX-UHFFFAOYSA-P 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000012429 reaction media Substances 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- MXFOQZLUCVHVRD-UHFFFAOYSA-N 2-methylsulfonyloxyethyl-[2,3,4,5-tetrahydroxy-6-(2-methylsulfonyloxyethylamino)hexyl]azanium;chloride Chemical compound [Cl-].CS(=O)(=O)OCCNCC(O)C(O)C(O)C(O)C[NH2+]CCOS(C)(=O)=O MXFOQZLUCVHVRD-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010056677 Nerve degeneration Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002243 precursor Chemical group 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 125000005490 tosylate group Chemical group 0.000 claims 1
- 0 CCNc(cc(cc1)N2CCNCC2)c1-c1c(c(*)n[n]2)c2nc(C(C=C2)=C[C@@](C)C2O)c1C=O Chemical compound CCNc(cc(cc1)N2CCNCC2)c1-c1c(c(*)n[n]2)c2nc(C(C=C2)=C[C@@](C)C2O)c1C=O 0.000 description 6
- BRAMSVYPKQNVPZ-UHFFFAOYSA-N C=Nc(c1c2-c(cc(cc3)N4CCNCC4)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound C=Nc(c1c2-c(cc(cc3)N4CCNCC4)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O BRAMSVYPKQNVPZ-UHFFFAOYSA-N 0.000 description 1
- AISBXUDDKUAEJK-UHFFFAOYSA-N CC(C(C=C1)N2CCNCC2)C(N2)=C1c1c(c(-c3ccc[o]3)n[nH]3)c3nc(-c(cc3)ccc3O)c1C2=O Chemical compound CC(C(C=C1)N2CCNCC2)C(N2)=C1c1c(c(-c3ccc[o]3)n[nH]3)c3nc(-c(cc3)ccc3O)c1C2=O AISBXUDDKUAEJK-UHFFFAOYSA-N 0.000 description 1
- ZAFIRQAXNHTHDQ-UHFFFAOYSA-N CC(C)(c1c2-c(c(N3)c4)ccc4OCCCN4CCNCC4)NNc1nc(-c(cc1)ccc1O)c2C3=O Chemical compound CC(C)(c1c2-c(c(N3)c4)ccc4OCCCN4CCNCC4)NNc1nc(-c(cc1)ccc1O)c2C3=O ZAFIRQAXNHTHDQ-UHFFFAOYSA-N 0.000 description 1
- QGHJHVIGFMDNKI-QOBPCVTDSA-N CC(C1=C2c(cccc3)c3N3CCCN(CC4)C[C@@H]4N)=NNC1NC(c(cc1)ccc1O)=C2C3=O Chemical compound CC(C1=C2c(cccc3)c3N3CCCN(CC4)C[C@@H]4N)=NNC1NC(c(cc1)ccc1O)=C2C3=O QGHJHVIGFMDNKI-QOBPCVTDSA-N 0.000 description 1
- SFDZPEPRESDJRO-UHFFFAOYSA-N CC(Nc(c1c2-c(cccc3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O)=O Chemical compound CC(Nc(c1c2-c(cccc3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O)=O SFDZPEPRESDJRO-UHFFFAOYSA-N 0.000 description 1
- CXFZVOZVDPUNAZ-UHFFFAOYSA-N CC(Oc(cc1)ccc1-c(nc1[nH]nc(C)c1c1-c(ccc(N2CCNCC2)c2)c2N2)c1C2=O)=O Chemical compound CC(Oc(cc1)ccc1-c(nc1[nH]nc(C)c1c1-c(ccc(N2CCNCC2)c2)c2N2)c1C2=O)=O CXFZVOZVDPUNAZ-UHFFFAOYSA-N 0.000 description 1
- DUZDAODFLIGRER-FXBVVIMESA-N CC1(C=CC(c(nc2[nH]nc(C)c2c2-c(ccc(N(CC3)C[C@@H]3N)c3)c3N3)c2C3=O)=CC1)O Chemical compound CC1(C=CC(c(nc2[nH]nc(C)c2c2-c(ccc(N(CC3)C[C@@H]3N)c3)c3N3)c2C3=O)=CC1)O DUZDAODFLIGRER-FXBVVIMESA-N 0.000 description 1
- KIHUZYGBKDKCKJ-UHFFFAOYSA-N CC1(NN=C(C)C1=C1c(cccc2)c2N2CCN3CCNCC3)NC(C(CC3)=CC=C3O)=C1C2=O Chemical compound CC1(NN=C(C)C1=C1c(cccc2)c2N2CCN3CCNCC3)NC(C(CC3)=CC=C3O)=C1C2=O KIHUZYGBKDKCKJ-UHFFFAOYSA-N 0.000 description 1
- VGRLQCYMYHEJDR-UHFFFAOYSA-N CCN(C=Cc1c(c(N)n[nH]2)c2nc(-c2cc(F)cc(F)c2)c11)C1=O Chemical compound CCN(C=Cc1c(c(N)n[nH]2)c2nc(-c2cc(F)cc(F)c2)c11)C1=O VGRLQCYMYHEJDR-UHFFFAOYSA-N 0.000 description 1
- UXHARFGUYCEFSV-UHFFFAOYSA-N CCN(c(cc(cc1)N2CCNCC2)c1-c1c(C(C)NN2)c2nc(-c(cc2)ccc2O)c11)C1=O Chemical compound CCN(c(cc(cc1)N2CCNCC2)c1-c1c(C(C)NN2)c2nc(-c(cc2)ccc2O)c11)C1=O UXHARFGUYCEFSV-UHFFFAOYSA-N 0.000 description 1
- VOIWWCQDJGQURV-UHFFFAOYSA-N CCN(c(cc(cc1)N2CCNCC2)c1-c1c(c(C)n[nH]2)c2nc(-c2cc(F)cc(OCC)c2)c11)C1=O Chemical compound CCN(c(cc(cc1)N2CCNCC2)c1-c1c(c(C)n[nH]2)c2nc(-c2cc(F)cc(OCC)c2)c11)C1=O VOIWWCQDJGQURV-UHFFFAOYSA-N 0.000 description 1
- SQSSLHICODVADS-UHFFFAOYSA-N CCOC(CCC(Oc(cc1)ccc1-c(nc1[nH]nc(C)c1c1-c(ccc(N2CCNCC2)c2)c2N2)c1C2=O)=O)=O Chemical compound CCOC(CCC(Oc(cc1)ccc1-c(nc1[nH]nc(C)c1c1-c(ccc(N2CCNCC2)c2)c2N2)c1C2=O)=O)=O SQSSLHICODVADS-UHFFFAOYSA-N 0.000 description 1
- QKNYNVVYXUCROE-UHFFFAOYSA-N CCOc(cc1)ccc1-c(nc1[nH]nc(C)c1c1-c(ccc(N2CCNCC2)c2)c2N2)c1C2=O Chemical compound CCOc(cc1)ccc1-c(nc1[nH]nc(C)c1c1-c(ccc(N2CCNCC2)c2)c2N2)c1C2=O QKNYNVVYXUCROE-UHFFFAOYSA-N 0.000 description 1
- RDVGLAYVBAYPFL-UHFFFAOYSA-N CNc1n[nH]c(nc2-c3cc(F)cc(F)c3)c1c(-c(ccc(N1CCNCC1)c1)c1N1)c2C1=O Chemical compound CNc1n[nH]c(nc2-c3cc(F)cc(F)c3)c1c(-c(ccc(N1CCNCC1)c1)c1N1)c2C1=O RDVGLAYVBAYPFL-UHFFFAOYSA-N 0.000 description 1
- VFJKEHJKOQTVQD-UHFFFAOYSA-N COc(cc1)ccc1-c(nc(c1c2-c(cc(cc3)N4CCNCC4)c3N3)[nH]nc1N)c2C3=O Chemical compound COc(cc1)ccc1-c(nc(c1c2-c(cc(cc3)N4CCNCC4)c3N3)[nH]nc1N)c2C3=O VFJKEHJKOQTVQD-UHFFFAOYSA-N 0.000 description 1
- UNXUTMIKXQPYND-UHFFFAOYSA-N Cc(c1c2-c(c(N3)c4)ccc4N4CCNCC4)n[nH]c1nc(-c(cc1)cc(C(O)=O)c1O)c2C3=O Chemical compound Cc(c1c2-c(c(N3)c4)ccc4N4CCNCC4)n[nH]c1nc(-c(cc1)cc(C(O)=O)c1O)c2C3=O UNXUTMIKXQPYND-UHFFFAOYSA-N 0.000 description 1
- PKDHDLWHMSRXDC-UHFFFAOYSA-N Cc(c1c2-c(ccc(N(CC3)CCC3N)c3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Cc(c1c2-c(ccc(N(CC3)CCC3N)c3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O PKDHDLWHMSRXDC-UHFFFAOYSA-N 0.000 description 1
- PGPROKLZRZRVMN-UHFFFAOYSA-N Cc(c1c2-c(ccc(N3CCNCC3)c3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Cc(c1c2-c(ccc(N3CCNCC3)c3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O PGPROKLZRZRVMN-UHFFFAOYSA-N 0.000 description 1
- JPPYTFFYCWKHCB-UHFFFAOYSA-N Cc(c1c2-c(ccc(N3CCNCC3)c3)c3N3)n[nH]c1nc(-c1cc(F)cc(O)c1)c2C3=O Chemical compound Cc(c1c2-c(ccc(N3CCNCC3)c3)c3N3)n[nH]c1nc(-c1cc(F)cc(O)c1)c2C3=O JPPYTFFYCWKHCB-UHFFFAOYSA-N 0.000 description 1
- CIAUWZWDZAFWRJ-UHFFFAOYSA-N Cc(c1c2-c(ccc(N3CCNCC3)c3)c3N3)n[nH]c1nc(Cc(ccc(F)c1)c1F)c2C3=O Chemical compound Cc(c1c2-c(ccc(N3CCNCC3)c3)c3N3)n[nH]c1nc(Cc(ccc(F)c1)c1F)c2C3=O CIAUWZWDZAFWRJ-UHFFFAOYSA-N 0.000 description 1
- PNMBUKUTHDIPNZ-UHFFFAOYSA-N Cc(c1c2-c(cccc3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Cc(c1c2-c(cccc3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O PNMBUKUTHDIPNZ-UHFFFAOYSA-N 0.000 description 1
- CJLBNEPWQZGVTQ-UHFFFAOYSA-N Cc(c1c2-c(cccc3)c3N3CCCN4CCN(C)CC4)n[nH]c1nc(C(C=C1)=CCC1O)c2C3=O Chemical compound Cc(c1c2-c(cccc3)c3N3CCCN4CCN(C)CC4)n[nH]c1nc(C(C=C1)=CCC1O)c2C3=O CJLBNEPWQZGVTQ-UHFFFAOYSA-N 0.000 description 1
- HGHUONOSEPFRQG-UHFFFAOYSA-N Cc(c1c2-c(cccc3)c3O3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Cc(c1c2-c(cccc3)c3O3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O HGHUONOSEPFRQG-UHFFFAOYSA-N 0.000 description 1
- UJVOPYYWHDSVTE-UHFFFAOYSA-N Cc(c1c2-c(cccc3)c3O3)n[nH]c1nc(-c(cc1)ccc1OC)c2C3=O Chemical compound Cc(c1c2-c(cccc3)c3O3)n[nH]c1nc(-c(cc1)ccc1OC)c2C3=O UJVOPYYWHDSVTE-UHFFFAOYSA-N 0.000 description 1
- YVPTVBBYIJFQSR-UHFFFAOYSA-N Cc(c1c2C(C=CC(C3)N(CC4)CCN4C4CCN(C)CC4)=C3N3)n[nH]c1nc(C(CC1)CC=C1O)c2C3=O Chemical compound Cc(c1c2C(C=CC(C3)N(CC4)CCN4C4CCN(C)CC4)=C3N3)n[nH]c1nc(C(CC1)CC=C1O)c2C3=O YVPTVBBYIJFQSR-UHFFFAOYSA-N 0.000 description 1
- NVTSGXNHTRFAGH-UHFFFAOYSA-N Cc(c1c2C=C(c3ccccc3)N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Cc(c1c2C=C(c3ccccc3)N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O NVTSGXNHTRFAGH-UHFFFAOYSA-N 0.000 description 1
- ZYBXUVKGKJGURP-UHFFFAOYSA-N Cc(c1c2C=C(c3ccccc3)O3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Cc(c1c2C=C(c3ccccc3)O3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O ZYBXUVKGKJGURP-UHFFFAOYSA-N 0.000 description 1
- QINTVVXXJQZLQB-UHFFFAOYSA-N Cc(c1c2C=CN3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Cc(c1c2C=CN3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O QINTVVXXJQZLQB-UHFFFAOYSA-N 0.000 description 1
- ROFJLUWRLYTVNA-UHFFFAOYSA-N Cc(c1c2C=CN3)n[nH]c1nc(-c1cc(F)cc(F)c1)c2C3=O Chemical compound Cc(c1c2C=CN3)n[nH]c1nc(-c1cc(F)cc(F)c1)c2C3=O ROFJLUWRLYTVNA-UHFFFAOYSA-N 0.000 description 1
- ROLCXCLFTMJBQY-UHFFFAOYSA-N Cc1cc(C(c2c(-c(cc3)cc(N(CC4)CCN4c(cc45)ccc4-c4c(c(-c6ccc[s]6)n[nH]6)c6nc(-c(c(F)c(cc6)F)c6F)c4C5=O)c3O)nc3[nH]nc(C)c3c2-2)=O)c-2[o]1 Chemical compound Cc1cc(C(c2c(-c(cc3)cc(N(CC4)CCN4c(cc45)ccc4-c4c(c(-c6ccc[s]6)n[nH]6)c6nc(-c(c(F)c(cc6)F)c6F)c4C5=O)c3O)nc3[nH]nc(C)c3c2-2)=O)c-2[o]1 ROLCXCLFTMJBQY-UHFFFAOYSA-N 0.000 description 1
- JNZWMVVXDUVVGL-UHFFFAOYSA-N Cc1n[nH]c2nc(-c(cc3)ccc3C#N)c(C(N(CCCN(C)C)c3c-4ccc(N5CCNCC5)c3)O)c-4c12 Chemical compound Cc1n[nH]c2nc(-c(cc3)ccc3C#N)c(C(N(CCCN(C)C)c3c-4ccc(N5CCNCC5)c3)O)c-4c12 JNZWMVVXDUVVGL-UHFFFAOYSA-N 0.000 description 1
- ZOGMMSCZCGCXHN-UHFFFAOYSA-N Cc1n[nH]c2nc(-c(cc3)ccc3O)c(cnc3c4cccc3)c4c12 Chemical compound Cc1n[nH]c2nc(-c(cc3)ccc3O)c(cnc3c4cccc3)c4c12 ZOGMMSCZCGCXHN-UHFFFAOYSA-N 0.000 description 1
- SDNCZQWNXSVYBP-UHFFFAOYSA-N NC(C1=C2c(ccc(N3CCNCC3)c3)c3N3)=NNC1NC(c(cc1)ccc1O)=C2C3=O Chemical compound NC(C1=C2c(ccc(N3CCNCC3)c3)c3N3)=NNC1NC(c(cc1)ccc1O)=C2C3=O SDNCZQWNXSVYBP-UHFFFAOYSA-N 0.000 description 1
- OXSQUZONCAHYCE-UHFFFAOYSA-N Nc(c1c2-c(cccc3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Nc(c1c2-c(cccc3)c3N3)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O OXSQUZONCAHYCE-UHFFFAOYSA-N 0.000 description 1
- SVNRSJZIVMKXER-UHFFFAOYSA-N Nc(c1c2-c(cccc3)c3N3O)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O Chemical compound Nc(c1c2-c(cccc3)c3N3O)n[nH]c1nc(-c(cc1)ccc1O)c2C3=O SVNRSJZIVMKXER-UHFFFAOYSA-N 0.000 description 1
- LZGIDGMWLNGISQ-UHFFFAOYSA-N Oc(cc1)ccc1C(N=C(C1C2c(cccc3)c3N3)NN=C1c(cc1)ccc1N1CCNCC1)=C2C3=O Chemical compound Oc(cc1)ccc1C(N=C(C1C2c(cccc3)c3N3)NN=C1c(cc1)ccc1N1CCNCC1)=C2C3=O LZGIDGMWLNGISQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1153200 | 2011-04-12 | ||
| FR1153200A FR2974088A1 (fr) | 2011-04-12 | 2011-04-12 | Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux |
| PCT/EP2012/056637 WO2012140114A1 (en) | 2011-04-12 | 2012-04-12 | Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510774A JP2014510774A (ja) | 2014-05-01 |
| JP2014510774A5 true JP2014510774A5 (enExample) | 2015-05-14 |
| JP5972964B2 JP5972964B2 (ja) | 2016-08-17 |
Family
ID=44512344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504312A Expired - Fee Related JP5972964B2 (ja) | 2011-04-12 | 2012-04-12 | 抗腫瘍剤としての三環式および四環式ピラゾロ［３，４−ｂ］ピリジン化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9085575B2 (enExample) |
| EP (1) | EP2697222A1 (enExample) |
| JP (1) | JP5972964B2 (enExample) |
| KR (1) | KR20140023341A (enExample) |
| CN (1) | CN103534254B (enExample) |
| AR (1) | AR085987A1 (enExample) |
| AU (1) | AU2012241891B2 (enExample) |
| BR (1) | BR112013026355A2 (enExample) |
| CA (1) | CA2832704A1 (enExample) |
| FR (1) | FR2974088A1 (enExample) |
| MX (1) | MX2013011854A (enExample) |
| RU (1) | RU2013148922A (enExample) |
| TW (1) | TWI560187B (enExample) |
| WO (1) | WO2012140114A1 (enExample) |
| ZA (1) | ZA201307783B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| JP6487527B2 (ja) | 2014-07-04 | 2019-03-20 | チル ファーマシューティカル カンパニー リミテッド | スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ） |
| CN104447736B (zh) * | 2014-10-14 | 2016-06-08 | 雅安职业技术学院 | 一种veranamine的合成方法 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9974784B2 (en) * | 2015-01-21 | 2018-05-22 | The Texas A&M University System | Inhibitors of activin-like receptor kinases |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20230303570A1 (en) * | 2020-08-07 | 2023-09-28 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN118891264A (zh) | 2022-08-01 | 2024-11-01 | 齐鲁制药有限公司 | 螺环胺类芳基磷氧化合物的晶型及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7872014B2 (en) * | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| MX2008002165A (es) * | 2005-08-16 | 2008-04-29 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina cinasa. |
| CN101525497B (zh) * | 2008-03-06 | 2012-07-04 | 中国科学院理化技术研究所 | 吡唑啉吡啶并苯并香豆素荧光染料衍生物及其合成方法和用途 |
| US20100113415A1 (en) * | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
-
2011
- 2011-04-12 FR FR1153200A patent/FR2974088A1/fr active Pending
-
2012
- 2012-04-11 AR ARP120101242A patent/AR085987A1/es not_active Application Discontinuation
- 2012-04-11 TW TW101112790A patent/TWI560187B/zh not_active IP Right Cessation
- 2012-04-12 EP EP12714688.4A patent/EP2697222A1/en not_active Withdrawn
- 2012-04-12 CN CN201280023479.XA patent/CN103534254B/zh not_active Expired - Fee Related
- 2012-04-12 CA CA2832704A patent/CA2832704A1/en not_active Abandoned
- 2012-04-12 RU RU2013148922/04A patent/RU2013148922A/ru not_active Application Discontinuation
- 2012-04-12 MX MX2013011854A patent/MX2013011854A/es not_active Application Discontinuation
- 2012-04-12 BR BR112013026355A patent/BR112013026355A2/pt not_active IP Right Cessation
- 2012-04-12 WO PCT/EP2012/056637 patent/WO2012140114A1/en not_active Ceased
- 2012-04-12 AU AU2012241891A patent/AU2012241891B2/en not_active Ceased
- 2012-04-12 KR KR1020137029401A patent/KR20140023341A/ko not_active Withdrawn
- 2012-04-12 JP JP2014504312A patent/JP5972964B2/ja not_active Expired - Fee Related
- 2012-04-12 US US14/111,098 patent/US9085575B2/en not_active Expired - Fee Related
-
2013
- 2013-10-18 ZA ZA2013/07783A patent/ZA201307783B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
| JP2014503574A5 (enExample) | ||
| JP2011529073A5 (enExample) | ||
| JP2017524025A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2018522867A5 (enExample) | ||
| JP2018522866A5 (enExample) | ||
| JP2012530713A5 (enExample) | ||
| WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
| JP2011509309A5 (enExample) | ||
| NZ593712A (en) | Intermediates for synthesising nucleoside aryl phosphoramidates | |
| JP2017519754A5 (enExample) | ||
| JP2018529690A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| WO2012172438A2 (en) | Compositions and methods for modulating a kinase | |
| JP2009542787A5 (enExample) | ||
| JP2016540803A5 (enExample) | ||
| JP2011509302A5 (enExample) | ||
| US20190202826A1 (en) | Phosphotidylinositol 3-Kinase Inhibitors | |
| JP2007532627A5 (enExample) | ||
| JP2020500872A (ja) | 癌を処置するための併用療法 | |
| JP2012515210A5 (enExample) | ||
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| JP2019521964A5 (enExample) | ||
| JP2011510026A5 (enExample) |